AI Health Technology Limited
智慧健康科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1715)

ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2026

FINANCIAL HIGHLIGHTS

	Six months ended 30 June	
	2026	2025
	(Unaudited)	(Unaudited)
Revenue *(RMB'000)*	**42,972**	23,940
Gross profit *(RMB'000)*	**2,541**	2,404
Gross profit margin *(%)*	**5.9**	10.0
Net loss for the period *(RMB'000)*	**(19,484)**	(11,513)
Loss per share		
– Basic and diluted *(RMB)*	**(0.05)**	(0.08)

INTERIM RESULTS

The board (the "**Board**") of directors (the "**Directors**") of AI Health Technology Limited (the "**Company**") announces the unaudited interim consolidated results of the Company and its subsidiaries (collectively the "**Group**") for the six months ended 30 June 2026 (the "**Interim Period**"). These results have been reviewed by the Company's audit committee (the "**Audit Committee**").

CONDENSED CONSOLIDATED INTERIM STATEMENT OF COMPREHENSIVE INCOME

For the six months ended 30 June 2026

		Six months ended 30 June	
		2026	2025
		RMB'000	*RMB'000*
	Notes	**(Unaudited)**	(Unaudited)
Revenue	3	**42,972**	23,940
Cost of sales		**(40,431)**	(21,536)
Gross profit		**2,541**	2,404
Other (expense)/income		**(189)**	744
Other losses, net		**(18)**	(1)
Selling and distribution expenses		**(8,253)**	(6,579)
Administrative expenses		**(6,696)**	(5,440)
Research and development expenses		**(5,622)**	(2,265)
Impairment loss on investment		**–**	(658)
Reversal of impairment loss on financial assets		**330**	1,825
Operating loss		**(17,907)**	(9,970)
Finance income		**17**	1
Finance costs		**(1,419)**	(1,338)
Finance costs, net		**(1,402)**	(1,337)
Share of loss of associates, net		**(143)**	(189)
Loss before income tax		**(19,452)**	(11,496)
Income tax expense	5	**(32)**	(17)
Loss for the period		**(19,484)**	(11,513)
Loss attributable to:			
Owners of the Company		**(19,464)**	(11,500)
Non-controlling interests		**(20)**	(13)
		(19,484)	(11,513)

	Notes	Six months ended 30 June **2026** ***RMB'000*** **(Unaudited)**	 2025 *RMB'000* (Unaudited)
Other comprehensive (loss)/income:			
Items that may be reclassified to profit or loss			
Currency translation differences		**(1,118)**	1,041
Other comprehensive (loss)/income for the period, net of tax		**(1,118)**	1,041
Total comprehensive loss for the period		**(20,602)**	(10,472)
Total comprehensive loss attributable to:			
Owners of the Company		**(20,582)**	(10,459)
Non-controlling interests		**(20)**	(13)
Total comprehensive loss for the period		**(20,602)**	(10,472)
Loss per share attributable to owners of the Company for the period			
Basic and diluted *(RMB)*	6	**(0.05)**	(0.08)

CONDENSED CONSOLIDATED INTERIM STATEMENT OF FINANCIAL POSITION

As at 30 June 2026

	Notes	**30 June 2026** *RMB'000* **(Unaudited)**	31 December 2025 *RMB'000* (Audited)
ASSETS			
Non-current assets			
Property, plant and equipment		**9,234**	10,182
Land use rights		**7,625**	7,741
Investments in associates		**–**	–
Investments in joint venture		**–**	143
Intangible assets		**58**	80
Prepayments		**2,266**	3,852
Total non-current assets		**19,183**	21,998
Current assets			
Inventories		**12,955**	17,477
Trade receivables	7	**4,700**	6,227
Other receivables, deposits and prepayments		**15,169**	72,572
Amount due from a non-controlling interest		**1,338**	1,338
Cash and cash equivalents		**50,512**	27,074
Total current assets		**84,674**	124,688
Total assets		**103,857**	146,686
EQUITY AND LIABILITIES			
Equity attributable to owners of the Company			
Share capital		**315**	315
Share premium		**102,835**	102,835
Reserves		**(64,497)**	(44,347)
Attributable to owners of the Company		**38,653**	58,803
Non-controlling interests		**840**	860
Total equity		**39,493**	59,663

	Notes	**30 June 2026** *RMB'000* **(Unaudited)**	31 December 2025 *RMB'000* (Audited)
LIABILITIES			
Non-current liabilities			
Borrowings		**4,090**	4,270
Deferred tax liabilities		**405**	375
Total non-current liabilities		**4,495**	4,645
Current liabilities			
Trade and other payables	8	**14,857**	29,120
Borrowings		**35,407**	41,926
Amount due to associates		**1,000**	1,000
Amount due to a joint venture		**510**	510
Amount due to a director		**3,177**	3,269
Contract liabilities		**4,708**	6,134
Current income tax liabilities		**210**	419
Total current liabilities		**59,869**	82,378
Total liabilities		**64,364**	87,023
Total equity and liabilities		**103,857**	146,686

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

For the six months ended 30 June 2026

1 GENERAL INFORMATION AND BASIS OF PRESENTATION

1.1 General information of the Group

AI Health Technology Limited (the "**Company**") was incorporated in the Cayman Islands on 16 May 2017 as an exempted company with limited liability under the Companies Law (as revised) of the Cayman Islands. The address of the Company's registered office is Windward 3, Regatta Office Park, PO Box 1350, Grand Cayman KY1-1108, Cayman Islands.

The Company is an investment holding company and the Group mainly engages in the development, manufacturing and selling of kitchen appliances and health-related products in the People's Republic of China (the "**PRC**").

The Company's shares were listed on the Main Board of The Stock Exchange of Hong Kong Limited on 16 July 2018.

This condensed consolidated interim financial information is presented in Renminbi ("**RMB**"), unless otherwise stated.

1.2 Basis of preparation

The condensed consolidated interim financial information of the Group for the six months ended 30 June 2026 has been prepared in accordance with the applicable disclosure provisions of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, including compliance with Hong Kong Accounting Standard ("**HKAS**") 34 "Interim Financial Reporting" issued by the Hong Kong Institute of Certified Public Accountants ("**HKICPA**").

The interim financial report has been prepared in accordance with the same accounting policies adopted in the 2025 annual financial statements, except for the accounting policy changes that are expected to be reflected in the 2026 annual financial statements. Details of any changes in accounting policies are set out in note 2.

The preparation of an interim financial report in conformity with HKAS 34 requires management to make judgements, estimates, and assumptions that affect the application of policies and reported amounts of assets and liabilities, income, and expenses on a year-to-date basis. Actual results may differ from these estimates.

This interim financial report contains condensed consolidated financial statements and selected explanatory notes. The notes include an explanation of events and transactions that are significant to an understanding of the changes in financial position and performance of the Group since the 2025 annual financial statements. The condensed consolidated interim financial statements and the accompanying notes do not include all of the information required for a full set of financial statements prepared in accordance with HKFRS Accounting Standards.

The condensed financial statements are unaudited but have been reviewed by the audit committee of the Company.

2 ACCOUNTING POLICIES

The condensed consolidated financial statements have been prepared on the historical cost basis.

Except as described below, the accounting policies and methods of computation used in the condensed consolidated financial statements for the six months ended 30 June 2026 are consistent with those used in the Group's annual financial statements for the year ended 31 December 2025.

Application of amendments to HKFRS Accounting Standards

In the current interim period, the Group has applied the following amendments to HKFRS Accounting Standards issued by the HKICPA, for the first time, which are mandatorily effective for the Group's annual period beginning on 1 January 2026 for the preparation of the Group's condensed consolidated financial statements:

Amendments to HKFRS 9 and HKFRS 7	Amendments to the Classification and Measurement of Financial Instruments
Amendments to HKFRS 9 and HKFRS 7	Contracts Referencing Nature-dependent Electricity
Amendments to HKFRS Accounting Standards	Annual Improvements to HKFRS Accounting Standards – Volume 11

The application of the amendments to HKFRS Accounting Standards in the current interim period has had no material impact on the Group's financial position and performance for the current and prior periods and/or on the disclosures set out in those condensed consolidated financial statements.

The Group has not early applied any new or amended HKFRS Accounting Standards that are not yet effective for the current accounting period.

3 REVENUE AND SEGMENT INFORMATION

Disaggregation of revenue from contracts with customers

	Six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Type of goods		
Kitchen appliances	**12,866**	15,794
Health-related products	**30,106**	8,146
	42,972	23,940
Timing of revenue recognition		
At a point in time	**42,972**	23,940

The chief operating decision-makers have been identified as the executive directors of the Group. Management has determined the operating segments based on the information reviewed by the executive directors for the purpose of allocating resources and assessing performance. There are two components in internal reporting to the executive directors for the six months ended 30 June 2026 and 2025, one component is the development, manufacturing and selling of kitchen appliance and the other component is the selling of health-related products.

Segment information provide to the executive directors

The table below shows the segment information provided to the executive directors for the reportable segments for the six months ended 30 June 2026 and also the basis on which revenue is recognised:

Six months ended 30 June 2026	**Development, manufacturing and selling of kitchen appliance** *RMB'000* **(Unaudited)**	**Selling of health-related products** *RMB'000* **(Unaudited)**	**Total** *RMB'000* **(Unaudited)**
Segment revenue	**12,866**	**30,106**	**42,972**
Segment loss	**(9,010)**	**(234)**	**(9,244)**
Unallocated expenses			**(8,663)**
Share of loss of associates, net			**(143)**
Finance costs, net			**(1,402)**
Loss before income tax			**(19,452)**

The table below shows the segment information provided to the executive directors for the reportable segments for the six months ended 30 June 2025 and also the basis on which revenue is recognised:

Six months ended 30 June 2025	Development, manufacturing and selling of kitchen appliance *RMB'000* (Unaudited)	Selling of health-related products *RMB'000* (Unaudited)	Total *RMB'000* (Unaudited)
Segment revenue	15,794	8,146	23,940
Segment loss	(7,784)	(20)	(7,804)
Unallocated expenses			(2,166)
Share of loss of associates, net			(189)
Finance costs, net			(1,337)
Loss before income tax			(11,496)

There are no inter-segment sales for the six months ended 30 June 2026 and 2025.

All of the segment revenue reported above is from external customers.

Segment (loss)/profit represents the (loss incurred)/profit earned by each segment without allocation of share of net loss of associates, net finance costs and unallocated expenses.

The Group's activities are mainly carried out in the PRC and the majority of the Group's assets and liabilities are located in the PRC. Non-current assets of RMB19,183,000 (31 December 2025: RMB21,998,000) of the Group are located in the PRC as at 30 June 2026. For the six months ended 30 June 2026, revenue of approximately RMB28,263,000 (2025: RMB13,298,000) was derived from two (2025: three) individual external customers, each of which contributed more than 10% of Group's revenue.

4 EXPENSES BY NATURE

Expenses included in cost of sales, selling and distribution expenses, administrative expenses and research and development expenses are analysed as follows:

	Six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Cost of materials used	**40,431**	21,536
Auditor's remuneration	**325**	889
Amortisation of intangible assets	**22**	42
Depreciation of property, plant and equipment	**899**	1,051
Depreciation of right-of-use assets	**–**	245
Amortisation of land use rights	**116**	105
Employee benefit expenses (including directors' emoluments)	**1,990**	4,303
Consignment fee	**105**	546
Short-term leases expenses	**5**	211

5 INCOME TAX EXPENSE

	Six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Current income tax	**–**	–
Deferred income tax	**32**	17
	32	17

Income tax expense is recognised based on management's estimate of the weighted average effective annual income tax rate expected for the full financial year.

6 LOSS PER SHARE

(a) Basic

	Six months ended 30 June	
	2026	2025
	(Unaudited)	(Unaudited)
Loss attributable to owners of the Company *(RMB'000)*	**(19,464)**	(11,500)
Weighted average number of ordinary shares in issue *(Note)*	**360,759,879**	141,119,472
Basic loss per share *(RMB)*	**(0.05)**	(0.08)

Note: The weighted average number of ordinary shares used to calculate the basic and diluted loss per share for the six months ended 30 June 2026 and 2025 have been adjusted to reflect the rights issue which was completed in 2025 and the share consolidation that became effective on 2 April 2024.

(b) **Diluted**

During the period, the diluted loss per share was the same as the basic loss per share as the computation of the diluted loss per share does not assume the exercise of the Company's share options because the assumed exercise would result in a decrease in loss per share (six months ended 30 June 2025: diluted loss per share is the same as the basic loss per share as there were no potential dilutive ordinary shares in existence during the period).

7 TRADE RECEIVABLES

	30 June 2026 *RMB'000* **(Unaudited)**	31 December 2025 *RMB'000* (Audited)
Trade receivables	**16,411**	18,268
Less: loss allowance	**(11,711)**	(12,041)
Trade receivables, net	**4,700**	6,227

The carrying amounts of the trade receivables approximate their fair value and are denominated in RMB.

The Group's credit terms to trade receivables are generally 60 to 270 days.

As at 30 June 2026, the ageing analysis of gross trade receivables, based on invoice date, is as follows:

	30 June 2026 *RMB'000* **(Unaudited)**	31 December 2025 *RMB'000* (Audited)
Trade receivables, by invoice date:		
1–30 days	**3,283**	2,935
31–60 days	**1**	3,052
61–90 days	**525**	118
Over 90 days	**12,602**	12,163
	16,411	18,268

8 TRADE PAYABLES

As at 30 June 2026, the ageing analysis of the trade payables based on invoice date is as follows:

	30 June 2026 *RMB'000* **(Unaudited)**	31 December 2025 *RMB'000* (Audited)
1–30 days	**9,567**	8,498
31–60 days	**–**	677
61–90 days	**307**	1,353
Over 90 days	**4,983**	6,759
	14,857	17,287

9 DIVIDENDS

No dividend was declared by the Company during the six months ended 30 June 2026 and 2025.

10 EVENTS OCCURRING AFTER THE REPORTING PERIOD

Save as disclosed elsewhere in this announcement, no significant events affecting the Group have occurred since the end of the reporting period and up to the date of this announcement.

MANAGEMENT DISCUSSION AND ANALYSIS

BUSINESS OVERVIEW AND OUTLOOK

Business Overview

The Group is principally engaged in developing, manufacturing and selling kitchen appliances and health-related products. Through a diversified omni-channel sales network comprising distributors, offline consignment arrangements, television e-commerce, online platforms and direct corporate clients, the Group has established nationwide market coverage and continues to deepen its presence in the domestic consumer market.

During the Interim Period, intensified competition in the domestic consumer market, together with external factors including fluctuations in industry demand, exerted pressure on the Group's traditional kitchen appliances business. To safeguard its core operations, the Group proactively implemented a series of optimisation measures, including continuous refinement of its product portfolio, integration and optimisation of its omni-channel layout, and the implementation of refined cost controls, with a view to fully unlocking the potential of the existing market and mitigating the pressure on its traditional business.

While consolidating its traditional core business, the Group accelerated its strategic expansion into the health industry. It has completed the establishment and commencement of operations of subsidiaries in Guangzhou, Beijing, Qingdao and other locations, and has built a mature and comprehensive health industry operating platform supported by an efficient supply chain system. These initiatives have laid a solid foundation for the scalable development of the Group's health business. Benefiting from the rapid growth of the health segment, the Group's overall revenue for the Interim Period increased significantly by 79.5% year-on-year from RMB23.9 million in the corresponding period of the previous year to RMB42.97 million.

The Group's overall gross profit margin declined from 10.0% in the corresponding period of the previous year to 5.9% in the Interim Period, primarily attributable to the substantial increase in the proportion of revenue derived from high-turnover, large-scale health products, which diluted overall profitability. The Group's net loss widened year-on-year during the period, which represents a normal transitional phase associated with strategic investments in new businesses. The principal contributing factors were: (i) an increase of approximately RMB1.6 million in selling and distribution expenses, mainly reflecting increased investment in channel development, marketing and terminal operations to expand the health business and enhance brand influence; (ii) an increase of approximately RMB1.3 million in administrative expenses, primarily due to the recruitment of additional core operational and management personnel and related operating costs to support the expansion of the health business; and (iii) an increase of approximately RMB3.4 million in research and development expenses, mainly attributable to the Group's continued investment in the digitalisation of the health sector, with focused resources devoted to the development of an integrated intelligent health platform system to strengthen the technological barriers of the new business.

Business Outlook

Looking ahead, the Group will continue to focus on the core segments of the health industry, with particular emphasis on two key areas: the development of a digital health platform and the upgrading of its omni-channel capabilities. Leveraging its proprietary and licensed core software and hardware technologies, and concentrating on the dual priorities of health data analysis and intelligent health services, the Group will continuously iterate and enhance its one-stop, full-lifecycle health management platform to achieve precise monitoring of health data across all population groups and scenarios. Concurrently, the Group will deepen the practical application of artificial intelligence and big data technologies, establishing an intelligent service system based on user health data to deliver scientific and personalised health solutions and management services, thereby further enhancing the platform's core value and user stickiness.

In terms of industry expansion, the Group will pursue a dual-track strategy of external expansion and organic growth. It will actively identify and engage with quality targets in the health industry that possess mature core technologies, stable market channels and strong development potential. Fully utilising the advantages of its listed company platform, capital resources and brand assets, the Group will accelerate the integration of high-quality resources through strategic cooperation, equity investments and industrial mergers and acquisitions, so as to rapidly address business shortfalls, expand industrial scale and accelerate the commercialisation of its health business.

At the overall operational level, the Group will adhere to a prudent yet progressive operating principle, continuously optimising its business structure, balancing the development pace between its traditional kitchen appliances business and its new health business, deepening synergistic collaboration with strategic partners, and steadily advancing a diversified and high-quality business layout. At the same time, the Group will continue to strengthen refined capital management, optimise resource allocation efficiency, strictly control operational risks, and enhance overall operational capability and earnings quality. Going forward, the Group will continue to consolidate its core competitiveness, steadily unlock the growth momentum of its new businesses, and strive to deliver stable and sustainable long-term returns to all shareholders.

FINANCIAL REVIEW

Revenue

Revenue by product categories

The Group derives its revenue from the sales of (i) radiant hobs and stoves; (ii) induction hobs and stoves; (iii) pots and pans; (iv) other small kitchen appliances and kitchen cabinets; and (v) health-related products. The Group's total revenue for the Interim Period increased by 79.5% to approximately RMB43.0 million from RMB23.9 million for the six months ended 30 June 2025.

Set out below is a breakdown of revenue by product categories for the Interim Period:

	Six months ended 30 June			
	2026		2025	
	RMB'000	***% of total revenue***	*RMB'000*	*% of total revenue*
Hobs and stoves (Radiant)	**10,214**	**23.8**	10,151	42.4
Hobs and stoves (Induction)	**642**	**1.5**	684	2.9
Pots and pans	**369**	**0.9**	3,427	14.3
Health-related products	**25,055**	**58.3**	8,146	34.0
Others *(Note)*	**6,692**	**15.5**	1,532	6.4
Total	**42,972**	**100.0**	23,940	100.0

Note: Others include small kitchen appliances such as hoods, kettles, bakery ovens and kitchen cabinets.

Revenue by geographical regions

During the six months ended 30 June 2026 and 2025, the Group's revenue was substantially derived in the PRC.

Revenue by sales channels

The Group sells its products through various channels, mainly including its consignment stores, sales to corporate clients, sales from television platforms and online platforms and physical sales locations operated by the Group's distributors. Set out below is a breakdown of revenue by sales channels for the Interim Period:

	Six months ended 30 June			
	2026		2025	
	RMB'000	***% of total revenue***	*RMB'000*	*% of total revenue*
Direct Sales				
Consignment stores	**4,080**	**9.5**	6,273	26.2
Corporate clients	**44**	**0.1**	358	1.5
Television platform	**122**	**0.3**	1,193	5.0
Subtotal	**4,246**	**9.9**	7,824	32.7
Distributors				
Online platform	**6,681**	**15.5**	6,133	25.6
Physical sales locations	**32,045**	**74.6**	9,983	41.7
Subtotal	**38,726**	**90.1**	16,116	67.3
Total	**42,972**	**100.0**	23,940	100.0

Consignment stores

During the Interim Period, the Group's direct sales revenue from consignment stores decreased by 35.0% to RMB4.1 million from RMB6.3 million for the six months ended 30 June 2025, primarily attributable to the decreased in consumer spending amid the trend of consumption.

Corporate clients

During the Interim Period, the Group's sales revenue from corporate clients decreased by 87.7% to RMB0.04 million from RMB0.4 million for the six months ended 30 June 2025, primarily attributable to the decrease in sales orders from PRC property developers.

Television platform

During the Interim Period, the Group's direct sales revenue from television platforms decreased by 89.8% to RMB0.1 million from RMB1.2 million for the six months ended 30 June 2025, primarily attributable to (i) the decrease in consumer spending amid the trend of consumption downgrading and (ii) the decrease in sales of kitchen appliance products.

Online platform

During the Interim Period, the Group's sales revenue from online platforms operated by the Group's distributors increased by 8.9% to RMB6.7 million from RMB6.1 million for the six months ended 30 June 2025. The increase in sales revenue from online platforms operated by the Group's distributors was attributable to the increasing consumer preference for selecting and purchasing products from merchants on social media platform.

Physical sales locations

During the Interim Period, the Group's sales revenue from physical sales locations increased by 221.0% to RMB32.0 million from RMB10.0 million for the six months ended 30 June 2025, primarily attributable to the increase in sales of health-related products.

Gross profit and gross profit margin

The Group's overall gross profit margin declined from 10.0% in the corresponding period of the previous year to 5.9% in the current period, primarily attributable to the significant increase in the proportion of revenue generated from the high-turnover, low-gross-margin health business, which diluted overall profitability.

Other (expense)/income

Other (expense)/income mainly includes government grant, licensing income, management fee income, sundry income and other expenses. The Group recorded other expenses of RMB0.2 million for the Interim Period as compared with other income RMB0.7 million for the six months ended 30 June 2025, primarily attributable to the decrease in licensing income and increase in other expenses.

Other losses

The Group recorded other losses of RMB18,000 for the Interim Period as compared with RMB1,000 for the six months ended 30 June 2025, no material movement during the Interim Period.

Selling and distribution expenses

Selling and distribution expenses mainly represent consignment fee for the Group's direct sales through consignment stores and television platforms, sundry expenses of consignment stores, salaries, performance bonuses and employee benefits expenses of sales and marketing staff, business travelling and entertainment expenses, advertising and promotion expenses, rental expenses and transportation expenses for delivery of products to customers. Selling and distribution expenses for the Interim Period increased by 25.4% to RMB8.3 million as compared with RMB6.6 million for the six months ended 30 June 2025. This was primarily attributable to the increase in intensified promotional and market development expenses in the health-related business.

Administrative expenses

Administrative expenses mainly represent salaries and benefits of our administrative and management staff, general office expenses, rental expenses, legal and professional fees, depreciation of property, plant and equipment, amortization of land use right and amortization of intangible assets, and other miscellaneous administrative expenses. Administrative expenses for the Interim Period increased by 23.1% to RMB6.7 million from RMB5.4 million for the six months ended 30 June 2025. The increase in administrative expenses for the Interim Period was primarily attributable to the increase in personnel and general operational costs incurred to support the development of health-related business.

Research and development expenses

Research and development expenses for the Interim Period increased by 148.2% to RMB5.6 million from RMB2.3 million for the six months ended 30 June 2025, primarily resulting from the Group's development of a new comprehensive marketing solution system.

Impairment loss on investment

Impairment loss on investment for the Interim Period decreased to RMB nil from RMB0.7 million for the six months ended 30 June 2025. As the relevant investment had been fully impaired in prior periods and its carrying amount was already reduced to nil. Accordingly, no further impairment movement was recorded during the Interim Period.

Reversal of impairment loss on financial assets

For the Interim Period, the Group recorded reversal of impairment loss on financial assets of RMB0.3 million, representing a decrease of impairment loss on financial assets by 81.9% from RMB1.8 million for the six months ended 30 June 2025, the amount of reversal was lower than that in the corresponding period in 2025, reflecting a closer alignment between the expected credit loss estimates and subsequent collection experience, while the relevant credit control and collection management processes continued to operate effectively.

Finance income

Finance income represents bank interest income. For the Interim Period, the Group's finance income increased to RMB17,000 from RMB1,000 for the six months ended 30 June 2025.

Finance costs

For the Interim Period, the Group's finance costs increased by 6.1% to RMB1.4 million as compared with RMB1.3 million for the six months ended 30 June 2025, primarily attributable to a higher proportion of high-interest borrowings.

Income tax expenses

For the Interim Period, the Group's income tax expenses increased to approximately RMB32,000 from RMB17,000 for the six months ended 30 June 2025, primarily attributable to the increase in tax assessable profits.

Net loss

For the reasons mentioned above, the Group recorded a net loss of RMB19.5 million for the Interim Period as compared with a net loss of RMB11.5 million for the six months ended 30 June 2025.

Dividend

The Board does not declare the payment of dividend for the Interim Period.

Other receivables, deposits and prepayments

	30 June 2026	31 December 2025
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Non-current		
Deposits	**2,266**	3,852
Current		
Deposits and prepayment	**10,304**	15,464
Receivable from a supplier	**–**	53,973
Other receivables	**4,218**	2,409
Value added tax recoverable	**1,149**	1,228
Less: Expected credit losses allowance of other receivables	**(502)**	(502)
Total	**17,435**	76,424

Prepayments mainly include prepayments to suppliers for the purchase of inventories and prepaid expenses. Prepayments decreased by 85.2% to RMB10.3 million as at 30 June 2026 from RMB69.4 million as at 31 December 2025. The decrease in the prepayments as at 30 June 2026 was mainly due to the decrease in receivable from a supplier.

Trade receivables

Trade receivables decreased by 24.5% to RMB4.7 million as at 30 June 2026 from RMB6.2 million as at 31 December 2025. The decrease in the trade receivables as at 30 June 2026 as the Group has been regularly liaising with the respective customers to ensure the eventual recovery of these amounts. The Group's credit terms to trade receivables are generally 60 to 270 days. As at 31 July 2026, 59.0% of the trade receivables (net of individual identified allowance) as at 30 June 2026 was subsequently settled.

CAPITAL STRUCTURE, LIQUIDITY, FINANCIAL RESOURCES AND GEARING RATIO

During the Interim Period, there was no material change to the capital structure of the Company.

As at 30 June 2026, the Company's issued share capital was HK$360,760 divided into 360,759,879 shares of HK$0.001 each.

The Group mainly funds its business and working capital requirements by using a balanced mix of internal resources, bank and other borrowings and proceeds from placing of the Company's shares. The funding mix will be adjusted depending on the costs of funding and the actual needs of the Group.

As at 30 June 2026, the Group had net current assets of approximately RMB24.8 million (31 December 2025: RMB42.3 million), cash and cash equivalents amounted to approximately RMB50.5 million (31 December 2025: RMB27.1 million) and borrowings amounted to approximately RMB39.5 million (31 December 2025: RMB46.2 million). The Group's cash and cash equivalents and borrowings as at 30 June 2026 were mainly denominated in RMB and HKD respectively. As at 30 June 2026, the Group had floating rate borrowings and fixed rate borrowings amounting to approximately RMB6.4 million (31 December 2025: RMB6.4 million) and RMB33.1 million (31 December 2025: RMB39.8 million), respectively. The weighted average interest rate of the Group's borrowings as at 30 June 2026 was approximately 4.33% (31 December 2025: 3.14%) per annum.

As at 30 June 2026, the Group had a current ratio of 1.4 times (31 December 2025: 1.5 times) and gearing ratio of 1.0 (calculated by dividing total borrowings by total equity) (31 December 2025: 0.8).

As at 30 June 2026 and 31 December 2025, the Group did not have any available unutilised banking facilities.

CAPITAL COMMITMENTS

As at 30 June 2026, the Group did not have any significant capital commitments (31 December 2025: nil).

CONTINGENT LIABILITIES

As at 30 June 2026, the Group did not have any material contingent liabilities or guarantees (31 December 2025: nil).

PLEDGE OF ASSETS

As at 30 June 2026, the Group pledged land use rights and buildings with carrying amount of approximately RMB13.2 million (31 December 2025: RMB13.9 million) to secure its borrowings of approximately RMB25.6 million (31 December 2025: RMB25.8 million).

MATERIAL ACQUISITIONS AND DISPOSALS OF ASSETS, SUBSIDIARIES, ASSOCIATES AND JOINT VENTURES

During the Interim Period, the Group did not have any material acquisitions and disposals of assets, subsidiaries, associates or joint ventures.

SIGNIFICANT INVESTMENTS HELD BY THE GROUP

During the Interim Period, the Group does not have any significant investments.

FUTURE PLAN FOR MATERIAL INVESTMENTS AND CAPITAL ASSETS

Saved as disclosed herein, during the Interim Period, the Group currently does not have any other future plans for material investments or capital assets.

FOREIGN EXCHANGE RISKS

The Group's foreign exchange risk mainly relates to fluctuations in exchange rates of RMB against its assets and liabilities in currencies other than RMB, and these may affect its operation results. The Group does not have a hedging policy. However, the Group's management monitors foreign exchange exposure and will consider hedging significant foreign currency exposure should the need arise.

EMPLOYEES AND REMUNERATION POLICY

As at 30 June 2026, the Group had a total of 60 employees (31 December 2025: 52 employees), whose remunerations and benefits are determined based on market rates, government policies and individual performance.

USE OF PROCEEDS IN RELATION TO RIGHTS ISSUE

On 17 June 2025, the Company completed the Rights Issue and on 18 June 2025, the Company issued 242,837,879 rights shares, on the basis of three rights shares for every one share, at a price of HK$0.25 per rights share ("**2025 Rights Issue**").

Upon completion of 2025 Rights Issue, the Company received net proceeds of approximately HK$58.9 million (the "**Net Proceeds**"). The Company intended to apply the Net Proceeds as to: (i) approximately HK$28.9 million for the repayment of the other borrowings, prioritizing repayment according to the maturity dates of each obligation; and (ii) the remaining approximately HK$30 million for the Group's general working capital for the daily operations of its existing principal business, including but not limited to (a) selling and distribution expenses of approximately HK$17.4 million; (b) administrative expenses of approximately HK$9.0 million; and (c) research and development expenses of approximately HK$3.6 million.

Further information of 2025 Rights Issue can be found in the Company's announcement dated 7 March 2025, 29 April 2025, 4 June 2025 and 17 June 2025, the circular of the Company dated 7 April 2025 and the prospectus of the Company dated 14 May 2025.

The following table sets forth the information in relation to the use of the Net Proceeds raised from the 2025 Rights Issue:

Intended use of net proceeds	**Original allocation of Net Proceeds** *HK$ million (approximately)*	**Utilised amount of Net Proceeds up to 30 June 2026** *HK$ million (approximately)*	**Unutilised amount of Net Proceeds up to 30 June 2026** *HK$ million (approximately)*	**Expected time period for the unutilised Net Proceeds**
Repayment of other borrowings of the Group	28.9	25.8	3.1	On or before 31 December 2026
Replenishment of the general working capital of the Group	30.0	19.3	10.7	On or before 30 June 2027
Total	58.9	45.1	13.8	

OTHER INFORMATION

DIRECTORS' AND CHIEF EXECUTIVE'S INTERESTS AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES OF THE COMPANY OR ANY ASSOCIATED CORPORATION

As at 30 June 2026, the interests and short positions of the Directors and chief executive of the Company in the ordinary share(s) of HK$0.001 each in the share capital of the Company (the "**Share(s)**") and underlying shares and debentures of the Company or its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong) (the "**SFO**")), as recorded in the register required to be kept by the Company pursuant to section 352 of the SFO, or as otherwise notified to the Company and the Stock Exchange pursuant to the Model Code for Securities Transaction by Directors of Listed Issuers (the "**Model Code**") as set out in Appendix C3 to The Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**"), and Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which were taken or deemed to have under such provisions of the SFO) are as follows:

To the best knowledge of the Directors, as at 30 June 2026, none of the Directors or chief executive of the Company and/or any of their respective associates had any interests or short positions in any shares and underlying shares in, and debentures of, the Company or any associated corporations, as recorded in the register required to be kept by the Company pursuant to Section 352 of the SFO, or as otherwise notified to the Company and the Stock Exchange pursuant to Part XV of the SFO or the Model Code.

ARRANGEMENT FOR DIRECTORS TO PURCHASE SHARES OR DEBENTURES

Saved as disclosed in this announcement and to the best knowledge of the Directors, at no time during the Interim Period, were rights to acquire benefits by means of the acquisition of shares in or debentures of the Company granted to any Director of the Company or their respective spouses or minor children, or were such rights exercised by them, or was the Company, its holding company or any of its subsidiaries a party to any arrangements to enable the Directors of the Company to acquire benefits by means of the acquisition of shares in, or debt securities (including debentures) of the Company or any other body corporate.

SUBSTANTIAL SHAREHOLDERS' AND OTHER PERSONS' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES OF THE COMPANY

As at 30 June 2026, the following persons (other than the interests of the Directors or chief executives of the Company as disclosed above) had interests or short positions in the ordinary shares of the Company or underlying shares which fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO or as recorded in the register required to be kept by the Company pursuant to section 336 of the SFO:

Name of Shareholders	**Capacity/ nature of interest**	**Number of Shares held** *(Note 1)*	**Percentage of shareholding in the Company** *(Approximate)*
Starlight Investment Fund SPC – Starlight Investment Fund SP6	Beneficial owner	100,000,000 (L)	27.72%
Huang Liming	Beneficial owner	12,000,000 (L)	3.33%
	Interest of spouse	10,000,000 (L) *(Note 2)*	2.77%
Li Mengya	Beneficial owner	10,000,000 (L)	2.77%
	Interest of spouse	12,000,000 (L) *(Note 3)*	3.33%

Notes:

1. The letter "L" denotes long position of the shares and the letter "S" denotes short position of the shares.

2. These 10,000,000 shares of the Company represented the shares beneficially owned by Ms. Li Mengya ("**Ms. Li**"). By virtue of the SFO, Mr. Huang Liming ("**Mr. Huang**"), being the spouse of Ms. Li, was deemed to be interested in all shares held by Ms. Li.

3. These 12,000,000 shares of the Company represented the shares beneficially owned by Mr. Huang. By virtue of the SFO, Ms. Li, being the spouse of Mr. Huang, was deemed to be interested in all shares held by Mr. Huang.

Save as disclosed above and to the best knowledge of the Directors, as at 30 June 2026, the Company has not been notified of any other relevant interests or short positions in the issued share capital of the Company which would fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO, or which were recorded in the register required to be kept by the Company under Section 336 of the SFO.

SHARE OPTION SCHEME

The Company conditionally adopted a share option scheme on 24 June 2018 (the "**2018 Share Option Scheme**"). The 2018 Share Option Scheme was terminated following the approval and adoption of new share option scheme by the shareholders at the annual general meeting held on 26 June 2026 (the "**2026 Share Option Scheme**").

Upon adoption of the 2026 Share Option Scheme on 26 June 2026, all the outstanding share options granted under the 2018 Share Option Scheme remain valid and exercisable in accordance with their terms. However, no further share options may be granted under the 2018 Share Option Scheme.

The 2018 Share Option Scheme

The purpose of which is to motivate the relevant participants to optimise their future contributions to the Group and/or to reward them for their past contributions, to attract and retain or otherwise maintain on-going relationships with such participants who are significant to and/or whose contributions are or will be beneficial to the performance, growth or success of the Group.

Details of the 2018 Share Option Scheme are set out in the 2025 Annual Report. Details of movement in the share options granted under the 2018 Share Option Scheme during the Interim Period are set out below:

Name of category of grantees	Date of grant	Vesting period	Period during which options are exercisable	Exercise price per share	Numbers of options outstanding as at 1 January 2026	Numbers of options granted during the period	Numbers of options exercised during the period	Numbers of options lapsed during the period	Numbers of options cancelled during the period	Numbers of options outstanding as at 30 June 2026
Employees	15 October 2025	15 October 2025 to 14 October 2026	15 October 2026 to 14 October 2035	HK$0.325	6,000,000	–	–	–	–	6,000,000

During the Interim Period, no share option was granted, exercised, cancelled or lapsed under the 2018 Share Option Scheme.

As at the date of this announcement, the total number of shares available for issue under the 2018 Share Option Scheme was 6,000,000 (after the share consolidation effective on 2 April 2024), representing approximately 1.66% of the issued shares of the Company.

As at 1 January 2026 and 30 June 2026, the number of share options available for grant under the 2018 Share Option Scheme was nil and nil respectively; and the number of shares that may be issued in respect of options granted under the 2018 Share Option Scheme during the Interim Period is 6,000,000, representing 1.66% of the weighted average number of shares of the relevant class in issue of the Company for the Interim Period.

The 2026 Share Option Scheme

The 2026 Share Option Scheme was adopted on 26 June 2026 pursuant to the passing of the relevant resolutions at the annual general meeting of the Company held on 26 June 2026 and took effect on 2 July 2026 upon the Listing Committee of the Stock Exchange granting approval for the listing of, and permission to deal in, the Shares to be issued pursuant to the 2026 Share Option Scheme.

The purpose of the 2026 Share Option Scheme is to enable the Directors to grant share option(s) to subscribe for shares in the share capital of the Company to Eligible Participants (as defined in the 2026 Share Option Scheme) as incentives or rewards (i) to recognise their contribution or potential contribution to the Group, and to enable the Company to recruit and retain key employees of the Group; (ii) to align their interests with those of the Company by providing them with the opportunity to acquire a proprietary interest in the Company; and (iii) to motivate them to contribute to the long-term growth and development of the Company with a view to enhance the value of the Company for the benefit of the Company and the shareholders as a whole.

The total number of Shares which may be allotted and issued or transferred upon exercise of all options to be granted under the 2026 Share Option Scheme would be 36,075,987 Shares, representing 10% of the total number of shares in issue (excluding treasury shares of the Company, if any) as at the date of adoption of the 2026 Share Option Scheme.

The vesting period in respect of any options shall not be less than 12 months. The Board may determine a shorter vesting period in respect of the options granted to grantees if the Board and the remuneration committee of the Company (as the case may be) deems appropriate under certain scenarios as specified in the 2026 Share Option Scheme.

The exercise price for the Shares under the 2026 Share Option Scheme in relation to each option offered to an eligible participant shall subject to the adjustment, be determined by the Board in its absolute discretion but in any event must be at least the higher of: (a) the closing price of the Shares as stated in the daily quotation sheets of the Stock Exchange on the Offer Date (as defined in the 2026 Share Option Scheme), which must be a Business Day (as defined in the 2026 Share Option Scheme); and (b) the average of the closing price of the Shares as stated in the daily quotation sheets of the Stock Exchange for the five Business Days immediately preceding the Offer Date.

An option shall be deemed to have been granted and accepted by the grantee and to have taken effect when the duplicate offer letter constituting acceptance of the option duly signed by the grantee, together with a remittance or payment in favour of the Company of HK$1.00 by way of consideration for the grant thereof is received by the company secretary of the Company on or before the relevant acceptance date. Such remittance or payment shall in no circumstances be refundable.

A summary of the principal terms of the 2026 Share Option Scheme is set out in the Appendix IV to the Company's circular dated 29 May 2026.

As at the date of this announcement, the total number of Shares issuable under the options granted under the 2026 Share Option Scheme was nil.

During the Interim Period, no options were granted by the Company and no options were exercised, cancelled or lapsed pursuant to the 2026 Share Option Scheme.

As at 1 January 2026 and 30 June 2026, the total number of shares options available for grant under the 2026 Share Option Scheme was nil and 36,075,987 respectively; and the number of shares in respect of options which had been granted and remained outstanding under the 2026 Share Option Scheme during the Interim Period was nil.

As at 30 June 2026, the total number of shares which may be issued upon exercise of all options granted under the 2026 Share Option Scheme and 2018 Share Option Scheme of the Company that involves the issuance of the new shares (if any), in aggregate will be 6,000,000, representing approximately 1.66% of the issued shares of the Company as at 30 June 2026 (i.e. 360,759,879).

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

Neither the Company nor any of its subsidiaries has purchased, sold or redeemed any of the Company's listed securities (including sale of treasury shares (the "**Treasury Shares**") within the meaning under the Listing Rules) during the Interim Period. As at 30 June 2026, the Company did not hold any Treasury Shares.

DIRECTORS' AND SUBSTANTIAL SHAREHOLDERS' INTEREST IN COMPETING INTERESTS OR CONFLICT OF INTEREST

During the Interim Period, the Directors are not aware of any business or interest of the Directors, the substantial shareholders of the Company and their respective associates (as defined in the Listing Rules) that competes or is likely to compete, either directly or indirectly, with the business of the Group and any other conflicts of interests which any such person has or may have with the Company.

REVIEW OF INTERIM RESULTS

The Audit Committee has reviewed the unaudited condensed consolidated interim financial information and the interim results for the six months ended 30 June 2026 and discussed the related financial matters with the Board.

CONSTITUTIONAL DOCUMENTS

Upon the shareholders' approval on 26 June 2026 at the annual general meeting of the Company, the Company has adopted the amended and restated memorandum of association and articles of association for the purpose of, among others, (i) reflecting and aligning the existing memorandum and articles of association with the latest regulatory requirements, including the latest requirements of the Listing Rules, in connection with the expanded paperless listing regime, the electronic dissemination of corporation communications by listed issuers, the new treasury shares regime under the Listing Rules and to facilitate the implementation of an uncertificated securities market; and (ii) making certain other consequential and/or housekeeping changes.

For further details, please refer to the announcement of the Company dated 27 April 2026 and the circular of the Company dated 29 May 2026.

MODEL CODE FOR DIRECTORS' SECURITIES TRANSACTIONS

The Company has adopted the Model Code set out in Appendix C3 of the Listing Rules as its code of conduct regarding Directors' securities transactions and all Directors have confirmed, upon specific enquiry made, that they complied with the Model Code during the Interim Period.

CORPORATE GOVERNANCE

The Board adopted a set of corporate governance practices which aligns with or is more restrictive than the requirements set out in the Corporate Governance Code (the "**CG Code**"), contained in Appendix C1 to the Listing Rules. The Board is of the view that the Company has complied with the code provisions set out in the CG Code during the Interim Period.

The Company regularly reviews its corporate governance practices to ensure they comply with the CG Code and align with the latest development.

EVENT AFTER THE REPORTING PERIOD

Save as disclosed elsewhere in this announcement, no significant events affecting the Group have occurred since the end of the reporting period and up to the date of this announcement.

DISCLOSURE OF INFORMATION ON DIRECTORS

With effect from 26 June 2026, Mr. Wu Huizhang retired as an executive Director.

With effect from 2 July 2026, Ms. Wang Jian is appointed as an executive Director.

With effect from 29 July 2026, an investment committee (the "**Investment Committee**") is established for the purpose of, among others, to handle affairs relating to the investment aspects of the Company. Mr. Zhao Jie has been appointed as the chairman of the Investment Committee while Mr. Shen Shujing and Ms. Zhang Yuanjie have been appointed as the members of the Investment Committee.

Save as disclosed herein, as at the date of this announcement, there has been no change to the information of the Directors and chief executives of the Company which is required to be disclosed pursuant to Rule 13.51B(1) of the Listing Rules.

PUBLICATION OF INTERIM RESULTS AND INTERIM REPORT

This interim results announcement is published on the websites of the Stock Exchange (www.hkex.com.hk) and the Company (www.aihealth-technology.com). The interim report of the Company for the six months ended 30 June 2026 will be dispatched to Shareholders and published on the aforementioned websites in due course.

By order of the Board
AI Health Technology Limited
Zhao Jie
Executive Director

Hong Kong, 26 August 2026

As at the date of this announcement, the executive Directors are Mr. Zhao Jie, Madam Maeck Can Yue and Ms. Wang Jian, the independent non-executive Directors are Mr. Lin Dongming, Mr. Shen Shujing and Ms. Zhang Yuanjie.